JP7482152B2 - 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景 - Google Patents

皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景 Download PDF

Info

Publication number
JP7482152B2
JP7482152B2 JP2021562812A JP2021562812A JP7482152B2 JP 7482152 B2 JP7482152 B2 JP 7482152B2 JP 2021562812 A JP2021562812 A JP 2021562812A JP 2021562812 A JP2021562812 A JP 2021562812A JP 7482152 B2 JP7482152 B2 JP 7482152B2
Authority
JP
Japan
Prior art keywords
pharma
mmol
acceptable salt
ceutically acceptable
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529371A (ja
JP2022529371A5 (cg-RX-API-DMAC7.html
Inventor
フィリップ エー. ガーケン,
ジャンフア チャオ,
Original Assignee
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー filed Critical セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー
Publication of JP2022529371A publication Critical patent/JP2022529371A/ja
Publication of JP2022529371A5 publication Critical patent/JP2022529371A5/ja
Application granted granted Critical
Publication of JP7482152B2 publication Critical patent/JP7482152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021562812A 2019-04-24 2020-04-23 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景 Active JP7482152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837827P 2019-04-24 2019-04-24
US62/837,827 2019-04-24
PCT/US2020/029466 WO2020219640A1 (en) 2019-04-24 2020-04-23 Pyrimidine jak inhibitors for the treatment of skin diseases

Publications (3)

Publication Number Publication Date
JP2022529371A JP2022529371A (ja) 2022-06-21
JP2022529371A5 JP2022529371A5 (cg-RX-API-DMAC7.html) 2023-04-04
JP7482152B2 true JP7482152B2 (ja) 2024-05-13

Family

ID=70779856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562812A Active JP7482152B2 (ja) 2019-04-24 2020-04-23 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景

Country Status (11)

Country Link
US (1) US11439641B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959213B1 (cg-RX-API-DMAC7.html)
JP (1) JP7482152B2 (cg-RX-API-DMAC7.html)
AR (1) AR118767A1 (cg-RX-API-DMAC7.html)
CA (1) CA3135388A1 (cg-RX-API-DMAC7.html)
ES (1) ES2994097T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067909T2 (cg-RX-API-DMAC7.html)
PL (1) PL3959213T3 (cg-RX-API-DMAC7.html)
TW (1) TW202106681A (cg-RX-API-DMAC7.html)
WO (1) WO2020219640A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
CN115925705B (zh) * 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
WO2022083687A1 (zh) * 2020-10-21 2022-04-28 南京明德新药研发有限公司 硒杂环类化合物及其应用
WO2022094174A1 (en) * 2020-10-30 2022-05-05 Children's Hospital Medical Center Compositions and methods for the treatment of esophageal conditions
AU2022270072A1 (en) 2021-05-03 2023-11-02 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
JP2024516299A (ja) * 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹の治療のためのルキソリチニブ
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191524A1 (en) 2015-05-28 2016-12-01 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
WO2018086547A1 (zh) 2016-11-10 2018-05-17 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2019084383A1 (en) 2017-10-27 2019-05-02 Theravance Biopharma R&D Ip, Llc PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31
TWI740288B (zh) 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
CN115925705B (zh) 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
CN113372364B (zh) 2020-03-10 2024-05-31 明慧医药(上海)有限公司 一类jak激酶抑制剂及其制备和应用
CN113372351A (zh) 2020-03-10 2021-09-10 明慧医药(杭州)有限公司 一类jak激酶抑制剂及其制备和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191524A1 (en) 2015-05-28 2016-12-01 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
WO2018086547A1 (zh) 2016-11-10 2018-05-17 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2019084383A1 (en) 2017-10-27 2019-05-02 Theravance Biopharma R&D Ip, Llc PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Also Published As

Publication number Publication date
EP3959213C0 (en) 2024-06-05
US20200338073A1 (en) 2020-10-29
JP2022529371A (ja) 2022-06-21
CA3135388A1 (en) 2020-10-29
AR118767A1 (es) 2021-10-27
US11439641B2 (en) 2022-09-13
EP3959213A1 (en) 2022-03-02
TW202106681A (zh) 2021-02-16
EP3959213B1 (en) 2024-06-05
WO2020219640A1 (en) 2020-10-29
PL3959213T3 (pl) 2024-11-04
HRP20241053T1 (hr) 2024-11-08
ES2994097T3 (en) 2025-01-17
HUE067909T2 (hu) 2024-11-28

Similar Documents

Publication Publication Date Title
JP7470713B2 (ja) Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
US11439641B2 (en) Pyrimidine JAK inhibitors for the treatment of skin diseases
US12172994B2 (en) Pyrimidine compound as JAK kinase inhibitor
CA3020506A1 (en) Pyrimidine compounds as jak kinase inhibitors
CA3125039A1 (en) Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
OA19911A (en) Pyrimidine compound as JAK kinase inhibitor.
HK40029509B (en) Pyrimidine compound as jak kinase inhibitor
HK40029509A (en) Pyrimidine compound as jak kinase inhibitor
EA041115B1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240426

R150 Certificate of patent or registration of utility model

Ref document number: 7482152

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150